Age Related Macular Degeneration News and Research

RSS

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application for marketing authorization for EYLEA (aflibercept) Injection for the treatment of patients with diabetic macular edema (DME) to the Japanese Ministry of Health, Labour and Welfare.

3 Mar 2014

Ophthotech reports net loss of $20.4 million for fourth quarter 2013

Ophthotech Corporation today announced financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the Company's business and product development programs.

27 Feb 2014

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).

26 Feb 2014

Ellex gets CE Mark approval for 2RT laser treatment of early stage AMD

Ellex Medical Lasers Limited, a pioneer in medical technologies for the diagnosis and treatment of eye disease, today announced that it has secured a CE Mark (Conformité Européenne) for its proprietary Retinal Rejuvenation Therapy (2RT) laser treatment of early Age-Related Macular Degeneration (AMD).

24 Feb 2014

Study reveals that color vision abnormalities increase with age

Abnormal color vision increases significantly with aging-affecting one-half or more of people in the oldest age groups, reports a study in Optometry and Vision Science, official journal of the American Academy of Optometry.

24 Feb 2014

Study indicates relationship between multivitamin supplement use and cataract risk in men

Long-term daily multivitamin supplement use may lower cataract risk in men, according to a study of nearly 15,000 male physicians published this month in Ophthalmology, the journal of the American Academy of Ophthalmology

21 Feb 2014

Newly developed compound may allow blind see light

Progressive degeneration of photoreceptors-the rods and cones of the eyes-causes blinding diseases such as retinitis pigmentosa and age-related macular degeneration. While there are currently no available treatments to reverse this degeneration, a newly developed compound allows other cells in the eye to act like photoreceptors. As described in a study appearing in the February 19 issue of the Cell Press journal Neuron, the compound may be a potential drug candidate for treating patients suffering from degenerative retinal disorders.

20 Feb 2014

Nutrition and exercise have significant impact on one's vision

With the New Year comes many resolutions, including resolving to exercise more and eat better. While many individuals understand that nutrition and exercise play an important role in helping to prevent diabetes, obesity, and cardiovascular disorders, not many may be aware that these two elements have a significant impact on one's vision as well. Dr. Sandy T. Feldman, a renowned ophthalmologist and corneal expert at Clearview Eye & Laser Center in San Diego, advises patients to examine their physical fitness and eating habits in order to achieve optimum vision.

11 Feb 2014

Moderate aerobic exercise helps preserve nerve cells in retina after damage

Moderate aerobic exercise helps to preserve the structure and function of nerve cells in the retina after damage, according to an animal study appearing February 12 in The Journal of Neuroscience. The findings suggest exercise may be able to slow the progression of retinal degenerative diseases.

9 Feb 2014

New gene therapy restores some sight in people born with inherited form of blindness

A new gene therapy has restored some sight in people born with an inherited, progressive form of blindness. The technique replaces a defective gene in the eye with a normal working copy of the gene using a single injection.

16 Jan 2014

Study finds nearly 70% of U.S. adults experience digital eye strain on using digital devices

A report released today at the 2014 Consumer Electronics Show by The Vision Council finds that nearly 70 percent of U.S. adults experience digital eye strain while on digital devices – including computers, tablets and smartphones.

9 Jan 2014

Melanocyte-secreted fibromodulin promotes angiogenic microenvironment

The decreased vision loss that accompanies age-related macular degeneration (AMD) is associated with abnormal blood vessel growth in the eye. Frequencies of AMD development are different among racial backgrounds, with occurrence of AMD highest among individuals of mixed European decent.

22 Dec 2013

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for standard review the Company's supplemental Biologics License Application for EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema.

18 Dec 2013

Study reveals new mechanism that may block formation of new blood vessels and cancer growth

A study led by researchers at Boston University School of Medicine demonstrates a new mechanism involving a signaling protein and its receptor that may block the formation of new blood vessels and cancer growth. The findings are published in the December issue of Science Signaling.

29 Nov 2013

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has received approval for the treatment of Macular Edema Following Central Retinal Vein Occlusion from the Japanese Ministry of Health, Labour and Welfare.

22 Nov 2013

Study shows patients at high-risk of CNV benefit from ForeseeHome device for earlier detection

The results of the Home Monitoring of the Eye (HOME) study, conducted in Age-Related Eye Disease Study 2 (AREDS2) clinical centers, executed by the EMMES Corporation and sponsored by Notal Vision Ltd. Tel Aviv, Israel, have been accepted for publication in Ophthalmology.

16 Nov 2013

Cardiovascular Institute researchers to showcase 22 abstracts at upcoming AHA Scientific Sessions

Researchers from the Cardiovascular Institute at Rhode Island, The Miriam and Newport hospitals will present 22 abstracts, both poster and oral presentations, at the upcoming American Heart Association Scientific Sessions, to be held in Dallas November 16-20, 2013. Scientific Sessions is the foremost cardiovascular research meeting in the U.S., with more than 18,000 cardiovascular experts from more than 105 countries in attendance.

16 Nov 2013

Oraya presents data from INTREPID study of stereotactic radiotherapy for treatment of wet AMD

Oraya® Therapeutics, Inc. announced today that initial three-year safety follow-up data from its INTREPID study of Oraya Therapy™ stereotactic radiotherapy for the treatment of wet age-related macular degeneration (AMD) were presented for the first time today during the America Academy of Ophthalmology's (AAO) annual meeting in New Orleans.

16 Nov 2013

Breast cancer drug appears to protect cells against UV radiation, inflammation

Exemestane, a synthetic steroid drug widely prescribed to fight breast cancers that thrive on estrogens, not only inhibits the production of the hormone, but also appears to protect cells throughout the body against damage induced by UV radiation, inflammation and other assaults, according to results of research by Johns Hopkins scientists.

8 Nov 2013

NEI-funded study explores methods to improve diagnosis, treatment of common eye diseases

If you've ever been sleep-deprived, you've probably had a firsthand glimpse of the blood vessels in your eyes. But what you haven't seen—and what many eye care professionals cannot see as well as they would like—are the vessels closest to the retina, the light-sensitive tissue at the back of the eye.

29 Oct 2013

Age Related Macular Degeneration News and Research

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Ophthotech reports net loss of $20.4 million for fourth quarter 2013

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Ellex gets CE Mark approval for 2RT laser treatment of early stage AMD

Study reveals that color vision abnormalities increase with age

Study indicates relationship between multivitamin supplement use and cataract risk in men

Newly developed compound may allow blind see light

Nutrition and exercise have significant impact on one's vision

Moderate aerobic exercise helps preserve nerve cells in retina after damage

New gene therapy restores some sight in people born with inherited form of blindness

Study finds nearly 70% of U.S. adults experience digital eye strain on using digital devices

Melanocyte-secreted fibromodulin promotes angiogenic microenvironment

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Study reveals new mechanism that may block formation of new blood vessels and cancer growth

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Study shows patients at high-risk of CNV benefit from ForeseeHome device for earlier detection

Cardiovascular Institute researchers to showcase 22 abstracts at upcoming AHA Scientific Sessions

Oraya presents data from INTREPID study of stereotactic radiotherapy for treatment of wet AMD

Breast cancer drug appears to protect cells against UV radiation, inflammation

NEI-funded study explores methods to improve diagnosis, treatment of common eye diseases

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News